Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021
Antibiotics,
Journal Year:
2025,
Volume and Issue:
14(1), P. 29 - 29
Published: Jan. 3, 2025
Background/Objectives:
Meropenem-vaborbactam
(MEV)
and
ceftazidime-avibactam
(CZA)
are
active
against
"urgent
threat"
pathogens
like
carbapenem-resistant
Enterobacterales
(CRE).
However,
few
studies
have
compared
outcomes
between
them.
Methods:
To
explore
comparative
of
MEV
vs.
CZA,
we
conducted
a
multicenter
retrospective
cohort
study
all
adult
hospitalized
patients
with
serious
infection
(sepsis,
urinary
tract
[UTI],
complicated
intraabdominal
[cIAI]
infection,
or
pneumonia)
within
the
PINC
AI
Database,
2019-2021.
Descriptive
statistics
two
groups
along
demographic
clinical
characteristics,
multiple
regression
derived
adjusted
outcomes.
Results:
Among
1,989,765
who
met
enrollment
criteria,
455
received
2320
CZA.
Compared
to
on
were
more
commonly
Caucasian
(68.1%
63.6%,
p
=
0.032)
Hispanic
(21.8%
12.8%,
<
0.001).
Their
mean
[SD]
Charlson
comorbidity
scores
did
not
differ
(3.6
[2.5]
3.5
[2.5],
0.403).
The
most
common
index
in
both
was
pneumonia,
though
it
less
prevalent
MEV-
than
CZA-treated
group
(48.1%
56.8%,
Fewer
one-third
respective
drug
2
days
onset
(30.6%
33.0%
0.313).
CZA
required
mechanical
ventilation
(35.0%
41.4%,
0.010).
treatment
associated
lower
mortality
(17.0%
[95%
CI
13.6%,
20.3%]
20.6%
19.0%,
22.2%],
0.048)
relative
Conclusions:
In
this
treated
either
for
their
infectious
syndrome,
hospital
mortality,
although
confidence
intervals
around
values
overlapped.
Language: Английский
Epidemiology and Genetic Traits of Carbapenemase-Producing Enterobacterales: A Global Threat to Human Health
Antibiotics,
Journal Year:
2025,
Volume and Issue:
14(2), P. 141 - 141
Published: Feb. 1, 2025
Carbapenemase-producing
Enterobacterales
(CPE)
represent
an
important
threat
to
global
health,
resulting
in
urgent
issue
clinical
settings.
CPE
often
exhibit
a
multidrug-resistant
(MDR)
phenotype,
thus
reducing
the
antimicrobial
armamentarium,
with
few
antibiotics
retaining
residual
activity
against
these
pathogens.
Carbapenemases
are
divided
into
three
classes
(A,
B,
and
D)
according
Ambler
classification
system.
Among
these,
KPC
(class
A),
NDM,
VIM,
IMP
B),
OXA-48-like
most
carbapenemases
terms
of
diffusion
impact.
has
been
observed
worldwide,
current
endemicity
multiple
territories
around
world.
In
this
context,
clonal
spread
plasmid-mediated
transmission
have
contributed
worldwide
among
different
species.
recent
years,
novel
molecules
showing
excellent
vitro
vivo
developed
CPE.
However,
emergence
traits
resistance
already
reported
several
cases,
mitigating
initial
promising
results.
This
review
aims
provide
updated
description
major
carbapenemases,
their
distribution,
future
perspectives
limit
CPEs.
Language: Английский